{
    "clinical_study": {
        "@rank": "3277", 
        "arm_group": [
            {
                "arm_group_label": "Single 150 mg PF-04950615 dose administered to the abdomen", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Single 150 mg PF-04950615 dose administered to the upper arm", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Single 150 mg PF-04950615 dose administered to the thigh", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to characterize the single dose pharmacokinetics of PF-04950616 following\n      subcutaneous injection to the abdomen, upper arm or the thigh."
        }, 
        "brief_title": "Pharmacokinetics And Relative Bioavailability Of PF-04950615 When Administered To The Abdomen, Thigh Or Upper Arm", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypercholesterolemia", 
        "condition_browse": {
            "mesh_term": "Hypercholesterolemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female subjects 18 to 65 years of age.\n\n          -  Body Mass Index (BMI) \u2264 33 kg/m2, and total body weight of 60 kg to 90 kg (132 lbs to\n             198 lbs).\n\n          -  Fasting LDL-C must be > 130 mg/dL (borderline high per NCEP ATP III criteria) at two\n             qualifying visits: initial screening (Days -28 to -14) and Day -7.\n\n        Exclusion Criteria:\n\n          -  Poorly controlled type 1 or type 2 diabetes mellitus (HbA1c > 9.0%).\n\n          -  History of a cardiovascular or cerebrovascular event (eg, MI, stroke, TIA) or related\n             procedure (eg, angioplasty) during the past year.\n\n          -  Subjects who meet the New York Heart Association (NYHA) criteria for congestive heart\n             failure (CHF) classes III or IV."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02043301", 
            "org_study_id": "B1481024"
        }, 
        "intervention": [
            {
                "arm_group_label": "Single 150 mg PF-04950615 dose administered to the abdomen", 
                "description": "Single 150 mg PF-04950615 dose administered SC to the abdomen", 
                "intervention_name": "PF-04950615", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Single 150 mg PF-04950615 dose administered to the upper arm", 
                "description": "Single 150 mg PF-04950615 dose administered SC to the upper arm", 
                "intervention_name": "PF-04950615", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Single 150 mg PF-04950615 dose administered to the thigh", 
                "description": "Single 150 mg PF-04950615 dose administered SC to the thigh", 
                "intervention_name": "PF-04950615", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "pharmacokinetics", 
            "bioavailability", 
            "PF-04950615"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1481024&StudyName=Pharmacokinetics%20And%20Relative%20Bioavailability%20Of%20PF-04950615%20When%20Administered%20To%20The%20Abdomen%2C%20Thigh%20Or%20Upper%20Arm"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anaheim", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92801"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "South Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33143"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Overland Park", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66212"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Overland Park", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66211"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1, Open-Label, Randomized, Single Dose, Parallel Group Study To Assess Injection Site Relative Bioavailability Of PF-04950615 Following Subcutaneous Administration In Adult Subjects With Hypercholesterolemia", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It is obtained from AUC (0 - t) plus AUC (t - inf).", 
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - inf)]", 
                "safety_issue": "No", 
                "time_frame": "85 days"
            }, 
            {
                "description": "Maximum observed plasma concentration", 
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "85 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02043301"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "85 days"
            }, 
            {
                "description": "A measure of the rate at which a drug substance is removed from blood divided by bioavailability", 
                "measure": "Apparent SC Clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "85 days"
            }, 
            {
                "description": "The time to reach maximum observed plasma concentration", 
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "85 day"
            }, 
            {
                "description": "A theoretical volume in which the total amount of drug is uniformly distributed to produce the desired plasma concentration divided by bioavailability", 
                "measure": "Apparent Volume of Distribution (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "85 days"
            }, 
            {
                "description": "The time measured for the terminal plasma concentration to decrease by one half", 
                "measure": "Plasma Terminal Elimination Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "85 days"
            }, 
            {
                "description": "Area under the LDL-C effect curve from time 0 to the last timepoint with measurable effect", 
                "measure": "Area under the LDL-C effect curve", 
                "safety_issue": "No", 
                "time_frame": "85 days"
            }, 
            {
                "description": "Maximum LDL-C lowering", 
                "measure": "Maximum LDL-C lowering", 
                "safety_issue": "No", 
                "time_frame": "85 days"
            }, 
            {
                "description": "Time to reach the maximum LDL-C lowering", 
                "measure": "Time to reach maximum LDL-C lowering", 
                "safety_issue": "No", 
                "time_frame": "85 days"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}